STANDARD TREATMENT WORKFLOW (STW)

Bacterial Skin Infections

Binod K Khaitan, Deepika Pandhi, Ananta Khurana, Dipankar De, Rahul Mahajan, Renu George, Vishal Gupta

¹All India Institute of Medical Sciences, New Delhi; ²University College of Medical Sciences, New Delhi; ³Dr. Ram Manohar Lohia Hospital, New Delhi; ⁴Postgraduate Institute of Medical Education and Research, Chandigarh; ⁵Postgraduate Institute of Medical Education and Research, Chandigarh; ⁶ Christian Medical College, Vellore; ⁷All India Institute of Medical Sciences, New Delhi

CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi Email: binodkhaitan@hotmail.com

CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Bacterial Skin Infections. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S81-S82.


DOI: https://doi.org/10.56450/JEFI.2024.v2i1Suppl.041

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.



July/ 202: icma Standard Treatment Workflow (STW) **BACTERIAL SKIN INFECTIONS** ICD-10-L01, L73.9, L08, L02, L03, A46, L00 Skin hygiene, advise on handwashing/local hygiene, avoidance of oil application, adequate nutrition 1. IMPETIGO CLINICAL FEATURES CLINICAL FATURES
Wet yellow brown crusts overlying red inflamed skin

• Types Non bullous (NBI; commoner), bullous (BI)

• Affected age group usually children

• Common sites Face (perinasal, perioral) > extremities; extensive with scabies/ atopic eczema For recurrent/ severe lesions: evaluate for nasal carriage, diabetes, underlying skin conditions (scabies, atopic dermatitis) **GENERAL** PRINCIPLES OF MANAGEMENT In immunocompromised/ diabetics: consider the need for gram negative coverage Topical antibiotics for 5 days
 Oral antibiotics for extensive involvement or numerous lesions, lymphadenopathy or in outbreaks to prevent transmission 2. ECTHYMA MANAGEMENT CLINICAL FEATURES CLINICAL FEATURES Black thick crust (eschar) with underlying ulcer & surrounding redness & edema Hair follicle centred pustule/ papule
Rule out non bacterial causes: oils, chemicals,
waxing, epilation, occlusive dressing
RECURRENT FOLLICULTIS Recurrent infection or Topical antibiotics for 5 days manausment

• Treat with oral antibiotics for 7 days

• Gentle crust removal may be attempted after
soakage with sterile saline; topical antibiotics
over the exposed ulcer · Anti-inflammatory: Paracetamol outbreak in multiple members of family may indicate nasal *Staphylococcus aureus* carriage or human-pet transmission 500mg/Ibuprofen 400mg SOS for pain relief 6. CUTANEOUS ABSCESS CLINICAL FEATURES Painful follicle centric nodule/ pus point/ impending bulla/ ulcer with marked surrounding erythema, edema and induration **CLINICAL FEATURES** Confluence of multiple closely spaced furuncles + pus draining from multiple follicular orifices CLINICAL FEATURES Painful, warm, red fluctuant skin swelling Commonly nape of neck> breasts, buttocks in uncontrolled diabetes HOSPITALIZATION AND IV TREATMENT FOR SEVERELY ILL PATIENTS • Inj Ceftriaxone 2g BD OR Inj Amoxicillin-clavulanate 1.2gm TDS • Alternatively - Inj Clindamycin 600-900mg TDS INCISION AND DRAINAGE INCISION AND DRAIMAGE
 Incision and drainage/ debridement
 Ancillary antibiotics if systemic inflammatory signs, associated septic phlebitis, multiple/ large abscesses, prominent cellulitis & immunocompromised state Oral antibiotics + Topical antibiotics to reduce contamination of surrounding skin FURUNCLE IMPETIGO ECTHYMA FOLLICULITIS CELLULITIS CLINICAL FEATURES Acute spreading infection of skin involving subcutaneous tissue; Painful, red, tender, diffuse CLINICAL FEATURES A more superficial, bright red, edematous, painful area with a clear demarcated edge; common sites: lower extremities>face. Often associated with lymphangitis and swelling mostly involving the limbs lymphadenopathy; broken skin/ portal of entry may be visualised CELLULITIS WITH BULLAE NILD
Typical cellulitis/ erysipelas with no focus of purulence MANAGEMENT
Outpatient treatment with oral antibiotics
Elevation of affected area (to allow for dependent drainage); treatment of predisposing factors
Anti-inflammatory (Ibuprofen 400mg BD, Indomethacin 75mg BD) • Typical cellulitis/ erysipelas with systemic signs of infection MANAGEMENT SEVERE
With poor response to oral antibiotics, immunocompromised, signs of deeper infection like bullae, skin sloughing or systemic signs of infection like hypotension, or with organ dysfunction

MANAGEMENT

Empiric broad spectrum IV antibiotic coverage CATEGORIZE DISEASE SEVERITY Hospitalization and parenteral antibiotics:
• Inj Ceftriaxone 2g BD OR coverage

• Vancomycin + Piperacillin/ tazobactum

• Surgical debridement

• Sensitivity profile based modification of antibiotics Inj Amoxicillin-clavulanate 1.2qm Alternatively (allergic to penicillins)
 Inj Clindamycin 600-900mg IV TDS INVESTIGATIONS

1. Swabs for gram staining and pus culture are desirable

2. Blood cultures and biopsies are not routinely recommended, but useful with co-morbid conditions (malignancy on chemotherapy, immunocompromised states, animal bites etc.) COMPLICATIONS
Subcutaneous abscesses, blistering (often haemorrhagic), ulceration, tissue necrosis, myositis, septicemia 9. STAPHYLOCOCCAL SCALDED SKIN SYNDROME Temperature >100.4 F, WBC>12,000 or < 4000/µL, heart rate > 90 bpm, or respiratory rate > 24/min may indicate sepsis Severe pain followed by deceptive absence may indicate necrotising faccities Superficial peeling of skin due to toxin producing strains of staphylococcus Starts as tender and warm erythema and progresses to localised or generalised exfoliation with fever, malaise +/- dehydration and electrolyte disturbances
 Follows a local staphylococcal infection of either skin, throat, nose, umbilicus, or gut
 Bacteria cannot be demonstrated from blisters (cultures from original site may be positive)

Treatment: preferably in-patient Mild cases: oral anti-staphylococcal antibiotics; severe cases: IV antibiotic
 Consider methicillin resistant Staphylococcus aureus (MRSA) coverage
 Usually remits within a week in children, high mortality in adults **PHARMACOTHERAPY** FOR NASAL CARRIERS IN ALL PATIENTS SUSPECT THE NEED FOR MRSA COVERAGE IF: ANTIBIOTICS FOR SKIN AND SOFT TISSUE INFECTIONS Poor immune status
 Severe systemic signs
 MRSA infection elsewhere
 If no improvement in 48-72 hours
 Penetrating trauma % Mupirocin ointment for 5 days a month PREFER B-LACTAMS IF ALLERGIC TO Amoxycillin 500mg TDS (25-50 mg/kg/day) PENICILLINS TOPICAL Erythromycin ANTIBIOTICS Cloxacillin 500mg QID (50mg/kg/day) Cephalexin 250-500mg ORAL ANTIBIOTICS FOR SUSPECTED 500mg QID (40 mg/kg/day) Mupirocin cream 2% IV ANTIBIOTICS FOR MRSA OR CONFIRMED MRSA INFECTION

Cotrimoxazole 2 DS tablets BD Vancomycin: 15 mg/kg BD Clindamycin Fusidic acid · Linezolid: 600 mg BD

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.iemr.org.in) for more information.

Obepartment of Health Research, Ministry of Health & Family Welfare, Covernment of India.

cream 2%

Framycetin

(20mg/kg/day) cream 1% Linezolid 600 mg BD

This antibiotic susceptibility patterns may vary with region and time

Doxycycline 100 mg BD
 Minocycine 200 mg BD
 Linezolid 600 mg BD

· Clindamycin: 600-900 mg

TDS

QID (25–50 mg/kg/day) Amoxicillin clavulanate

combination: 625mg TDS

300-600mg

BD/TID (20mg/kg/day)

© 2024 JEFI S82